Literature DB >> 6694410

Creatine phosphate: an additive myocardial protective and antiarrhythmic agent in cardioplegia.

L A Robinson, M V Braimbridge, D J Hearse.   

Abstract

The potential for enhancing myocardial protection by adding high-energy phosphates to cardioplegic solutions was investigated in a rat heart model of cardiopulmonary bypass and ischemic arrest. Creatine phosphate (CP) was evaluated as an additive to the St. Thomas' Hospital cardioplegic solution. Dose-response studies (CP 0 to 50 mmol/L) revealed 10.0 mmol/L as the optimal concentration which improved recovery of aortic flow and cardiac output after a 40 minute period of normothermic (37 degrees C) ischemic arrest from 21.2% +/- 5.4% and 32.8% +/- 4.6% in the CP-free control group to 82.5% +/- 3.7% and 82.6% +/- 4.2% (p less than 0.001), respectively. Creatine kinase (CK) leakage was reduced by 68.7% (p less than 0.001) in the CP group. With hypothermic (20 degrees C) ischemia (240 minutes) and multidose (every 30 minutes) cardioplegia, recoveries of aortic flow and cardiac output were improved from 33.1% +/- 8.4% and 42.2% +/- 7.7% in the CP-free control group to 77.9% +/- 4.2% and 79.6% +/- 4.3% (p less than 0.001), respectively, in the drug group. In addition to improving function and decreasing CK release, CP reduced reperfusion arrhythmias, significantly decreasing the time between cross-clamp removal and return of regular rhythm and also completely obviating the need for electrical defibrillation. 51Chromium-ethylenediaminetetraacetic acid (51Cr-EDTA), an extracellular space marker, was used to study the disappearance of CP from the cardioplegic solution during its stasis in the heart. Upon reperfusion, two thirds of the infused dose appeared unchanged in the coronary effluent; the remainder was either degraded or accumulated by the myocardium. Despite its alleged inability to enter the myocardial cell, exogenous CP exerts potent protective and antiarrhythmic effects when added to the St. Thomas' Hospital cardioplegic solution. Although the mechanism of action remains to be elucidated, it may involve binding or uptake of the drug.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6694410

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  6 in total

1.  Energy substrates, hormone responses and glucocorticoid binding in lymphocytes during intense physical exercise in humans following phosphocreatine administration.

Authors:  D V Vorobiev; E G Vetrova; I M Larina; I A Popova; A I Grigoriev
Journal:  Eur J Appl Physiol Occup Physiol       Date:  1996

2.  Protective effects of adenosine in rabbit sinoatrial node ischemia-reperfusion model in vivo: control of arrhythmia by hyperpolarization-activated cyclic nucleotide-gated (HCN)4 channels.

Authors:  Feng-Xu Yu; Jian-Juan Ke; Yong Fu; Bin Liao; Ying-Kang Shi
Journal:  Mol Biol Rep       Date:  2010-09-15       Impact factor: 2.316

3.  Participation of calcium ions in the molecular mechanism of cardioprotective action of exogenous phosphocreatine.

Authors:  E A Konorev; N V Medvedeva; I V Jaliashvili; V L Lakomkin; V A Saks
Journal:  Basic Res Cardiol       Date:  1991 Jul-Aug       Impact factor: 17.165

4.  FTY720 prevents ischemia/reperfusion injury-associated arrhythmias in an ex vivo rat heart model via activation of Pak1/Akt signaling.

Authors:  E Eroume A Egom; Yunbo Ke; Hanny Musa; Tamer M A Mohamed; Tao Wang; Elizabeth Cartwright; R John Solaro; Ming Lei
Journal:  J Mol Cell Cardiol       Date:  2009-10-21       Impact factor: 5.000

5.  Superoxide dismutase and the reduction of reperfusion-induced arrhythmias: in vivo dose-response studies in the rat.

Authors:  E Riva; A S Manning; D J Hearse
Journal:  Cardiovasc Drugs Ther       Date:  1987-08       Impact factor: 3.727

6.  Mitochondrial respiration in myocardial biopsy samples as a criterion of postischemic recovery of the cardiac contractility.

Authors:  V I Veksler; A N Khatkevich; G V Elizarova; V I Kapelko
Journal:  Basic Res Cardiol       Date:  1990 May-Jun       Impact factor: 17.165

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.